In summary, the treatment of valsartan capsules and sacubitril and valsartan sodium tablets in patients with hypertensive CHF can improve the patient's vascular endothelial function, increase serum APN levels, reduce MMP-9 and BNP levels, and improve the treatment efficacy of patients, which is worthy of clinical application. The gene discussed is NPPB; the disease is hypertensive disorder.